Back to top
more

Abbott Laboratories (ABT)

(Delayed Data from NYSE)

$127.29 USD

127.29
5,452,778

+1.10 (0.87%)

Updated Aug 1, 2025 03:59 PM ET

After-Market: $127.29 0.00 (0.00%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.75%
2Buy17.82%
3Hold9.58%
4Sell5.28%
5Strong Sell2.61%
S&P50011.30%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

  • Value Score A
  • Growth Score A
  • Momentum Score A
  • VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

C Value D Growth F Momentum F VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Bottom 30% (173 out of 246)

Industry: Medical - Products

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Zacks News

Zacks Equity Research

Edwards Lifesciences (EW) Q3 Earnings, Sales Lag, View Intact

by Zacks Equity Research

Edwards Lifesciences (EW) misses the Zacks Consensus Estimate on both the counts in Q3 due to adverse impact from recent natural disasters in the Caribbean and the United States.

    Zacks Equity Research

    Anthem's (ANTM) Q3 Earnings Beat Estimates, Improve Y/Y

    by Zacks Equity Research

    Anthem's (ANTM) strong third-quarter results were driven by solid enrollment growth.

      Zacks Equity Research

      PetMed (PETS) Tops Q2 Earnings & Sales Estimates, Margins Up

      by Zacks Equity Research

      The year-over-year rise in earnings of PetMed (PETS) was driven by an increase in sales and improved margins.

        Zacks Equity Research

        Centene (CNC) Tops Q3 Earnings & Revenues, Raises '17 View

        by Zacks Equity Research

        Centene's (CNC) strong third-quarter earnings were driven by solid revenue growth.

          Zacks Equity Research

          Varian Medical (VAR) Q4 Earnings: Is a Surprise in Store?

          by Zacks Equity Research

          We are upbeat about Varian Medical's oncology business that accounted for around 95% of the company's total revenue in fourth-quarter 2017.

            Zacks Equity Research

            Baxter International (BAX) Q3 Earnings: What's in Store?

            by Zacks Equity Research

            Baxter International Inc's (BAX) third quarter estimate revision trend is encouraging due to acquisitions and strategic collaborations to enhance its product portfolio.

              Zacks Equity Research

              Quest Diagnostics (DGX) Beats Earnings in Q3, Updates View

              by Zacks Equity Research

              Despite hurricanes related financial impact, Quest Diagnostics (DGX) posted year-over-year growth in Q3 on recent acquisitions, tie-ups and strength in several advanced diagnostic offerings.

                Zacks Equity Research

                Company News For Oct 19, 2017

                by Zacks Equity Research

                Companies in the News are: FOGO,ABT,AGN,EA

                  Zacks Equity Research

                  Varian Medical (VAR) Initiates Halcyon Treatment in Europe

                  by Zacks Equity Research

                  Varian (VAR) has been taking initiatives to gain customers for its broad spectrum of products, especially targeting emerging markets.

                    Zacks Equity Research

                    Abbott (ABT) Exceeds Q3 Earnings, '17 Guidance Narrowed

                    by Zacks Equity Research

                    Abbott (ABT) posted promising Q3 results primarily on the back of strong EPD sales and emerging market expansion.

                      Zacks Equity Research

                      Can Illumina (ILMN) Maintain Balanced Growth in Q3 Earnings?

                      by Zacks Equity Research

                      Illumina (ILMN) might gain from continued growth in Product as well as Service and other segments in the third quarter.

                        Zacks Equity Research

                        Abbott (ABT) Beats Earnings and Sales in Q3, Tweaks View

                        by Zacks Equity Research

                        Abbott (ABT) rides high on strength in all segments in Q3 earnings.

                          Zacks Equity Research

                          Will Edwards Lifesciences (EW) Gain on THVT in Q3 Earnings?

                          by Zacks Equity Research

                          Edwards Lifesciences (EW) will likely ride high in Q3 earnings banking on continued growth in its highly advanced Transcatheter Heart Valve Therapy space.

                            Zacks Equity Research

                            Can Nutrisystem (NTRI) Surprise Investors in Q3 Earnings?

                            by Zacks Equity Research

                            Nutrisystem's (NTRI) innovative products are expected to expand customer base that will eventually drive reactivation revenues in Q3.

                              Zacks Equity Research

                              What to Expect From Thermo Fisher (TMO) in Q3 Earnings

                              by Zacks Equity Research

                              Thermo Fisher (TMO) gears up for another quarter of strong analytical instruments segmental growth. Improvement is likely to be seen in applied markets too.

                                Zacks Equity Research

                                Phibro Animal Banks on Diverse Portfolio, Competition Rife

                                by Zacks Equity Research

                                Phibro Animal (PAHC) is consistently trying to expand its product portfolio to counter the tough competition in the animal health space.

                                  Zacks Equity Research

                                  Henry Schein (HSIC) Inks Distribution Agreement with Terason

                                  by Zacks Equity Research

                                  Henry Schein's (HSIC) distribution agreement with Terason to distribute the latter's uSmart 3200T NexGen is likely to boost its global Medical segment business.

                                    Zacks Equity Research

                                    Will PBM Slowdown Hamper Express Scripts (ESRX) Q3 Earnings?

                                    by Zacks Equity Research

                                    Lackluster performance in PBM product network and services segment is likely to mar Express Scripts' (ESRX) revenues in the third quarter.

                                      Zacks Equity Research

                                      Will Intuitive Surgical (ISRG) Disappoint in Q3 Earnings?

                                      by Zacks Equity Research

                                      We believe that the growing adoption of Intuitive Surgical's (ISRG) da Vinci system among physicians for general surgery, oncology, urology and gynecology procedures is a catalyst for the quarter.

                                        Zacks Equity Research

                                        Can CR Bard (BCR) Spring a Surprise This Earnings Season?

                                        by Zacks Equity Research

                                        We believe that the growing adoption of the company's flagship Lutonix drug coated-balloon will result in improved performance for CR Bard (BCR) in Q3.

                                          Zacks Equity Research

                                          The Zacks Analyst Blog Highlights: AbbVie, American Express, Abbott, United Technologies and VMWare

                                          by Zacks Equity Research

                                          The Zacks Analyst Blog Highlights: AbbVie, American Express, Abbott, United Technologies and VMWare

                                            Zacks Equity Research

                                            Can ResMed (RMD) Maintain Balanced Growth in Q1 Earnings?

                                            by Zacks Equity Research

                                            ResMed (RMD) may ride high in Q1 on continued growth in its domestic as well as overseas business.

                                              Zacks Equity Research

                                              Here's Why You Should Buy Thermo Fisher Scientific (TMO) Now

                                              by Zacks Equity Research

                                              Based on a wide range of fundamental factors, Thermo Fisher (TMO) is a great pick for now.

                                                Zacks Equity Research

                                                Here's Why Investors Should Buy Integra LifeSciences Now

                                                by Zacks Equity Research

                                                The market is upbeat about Integra LifeSciences' (IART) latest developments that include product launches and strategic buyouts.

                                                  Zacks Equity Research

                                                  TransEnterix Senhance Surgical Robotic System Wins FDA Nod

                                                  by Zacks Equity Research

                                                  TransEnterix (TRXC) works on expanding in robotic surgery consistently.